TABLE 2.
Differentially expressed miRNAs and its targets in UC.
| miRNA name | Target | Sample type | Research object | Expression states | References |
|---|---|---|---|---|---|
| miR-26b | DIP1, MDM2, CREBBP, BRCA1 | Tissue, blood | Promotes inflammation and CAC by miR-26b/DIP1/DAPK axis | ↑ | (Benderska et al., 2015) |
| miR-223 | NLRP3 | Tissue | Regulate innate immunity in intestinal inflammation | ↑ | (Neudecker et al., 2017; Macartney-Coxson et al., 2020; Wu et al., 2020) |
| CLDN8 | Tissue | Regulate IL23/Th17 pathway | ↑ | (Wang et al., 2016b; Li et al., 2020) | |
| C/EBPβ | Tissue | Inhibits intestinal macrophages and DCs showing pro-inflammatory phenotype | ↑ | (Sun et al., 2015; Zhou et al., 2015) | |
| miR-23a | LB1 | Tissue | Leads to impaired colon healing and genome instability by promoting DSB accumulation | ↑ | Butin-Israeli et al. (2019) |
| miR-155 | RAD51 | Tissue | Leads to impaired colon healing and genome instability by promoting DSB accumulation | ↑ | (Gasparini et al., 2014; Butin-Israeli et al., 2019) |
| JARID2 | Tissue | Induces Th17 cells differentiation | ↑ | (Xu et al., 2017; Liu et al., 2018b; Zhu et al., 2020b) | |
| C/EBPβ, SOCS1 | Tissue | Regulates the phenotype of macrophages | ↑ | (Li et al., 2018; Xiao et al., 2019; Zhou et al., 2019) | |
| IL13RA1 | Tissue | Regulates the function of epithelial cells | ↑ | (Martinez-Nunez et al., 2011; Gwiggner et al., 2018) | |
| miR-301a | BTG1 | Tissue | Increases the permeability of IECs and damages the intestinal barrier function | ↑ | He et al. (2017) |
| SNIP1 | Tissue, blood | Promotes differentiation of Th17 cells and expression of pro-inflammatory cytokines | ↑ | He et al. (2016) | |
| miR-200family | Snail | Tissue | Inhibits EMT of colonic mucosa | ↓ | (Perdigão-Henriques et al., 2016; Zidar et al., 2016) |
| Slug | Tissue | Inhibits EMT of colonic mucosa | ↓ | (Liu et al., 2013; Zidar et al., 2016) | |
| miR-214–3p | STAT6 | Tissue | Inhibits IFN-γ expression and intestinal inflammation | ↓ | Li et al. (2017) |
| PDLIM2, PTEN | Tissue | Activates NF-κB pathway and promotes intestinal inflammation | ↑ | (Polytarchou et al., 2015a; Zhang and Zhang, 2017b; Liu et al., 2019b) | |
| miR-206 | A3AR | Tissue | Activates NF-κB pathway and promotes intestinal inflammation | ↑ | Wu et al. (2017a) |
| miR-21 | PDCD4 | Tissue | Activates NF-κB, STAT3 and BCL-2, and promotes the survival of tumor cells | ↑ | (Ando et al., 2016; Shi et al., 2016; Sun et al., 2020; Hu et al., 2021) |
| miR-148a-3p | GP130, IKKα, IKKβ, TNFR2 | Tissue | Inhibits NF-κB and STAT3 pathways and tumorigenesis | ↓ | (Zhu et al., 2017; Raso et al., 2019) |
| miR-148a-5p | IL1R1 | Tissue | Inhibits NF-κB and STAT3 pathways and tumorigenesis | ↓ | Zhu et al. (2017) |
| miR-133α | AFTPH | Tissue | Promotes intestinal inflammation | ↑ | (Law et al., 2015; Law et al., 2016) |
| miR-193a-3p | IL17RD | Tissue | Inhibits carcinogenesis by down-regulating IL17RD | ↓ | (Pekow et al., 2017; Yu et al., 2019) |
| miR-31 | IL13RA1 | Tissue | Regulates the function of epithelial cells | ↑ | Gwiggner et al. (2018) |
↓ indicates inhibition/reduction of miRNA expression in the object described in the corresponding "sample type" item, while ↑ indicates increase/promotion; UC, ulcerative colitis; DAPK, death-associated protein kinase; DIP1, DAPK-interacting protein-1; MDM2, murine double minute-2; CREBBP, cyclic AMP response element-binding protein (CREB)-binding protein; BRCA1, breast cancer genes one; CAC, colitis-associated cancer; NLRP3, NOD-like receptor (NLR) family pyrin domain containing-3; CLDN8, claudin eight; Th17, T helper 17 cell; C/EBPβ, CCAAT/enhancer binding protein beta; DCs, dendritic cells; LB1, lamin B1; DSB, double-strand break; JARID2, jumonji and AT-rich interaction domain containing two; SOCS1, suppressor of cytokine signaling one; IL13RA1, interleukin 13 receptor subunit alpha one; BTG1, B-cell translocation gene-1; IECs, intestinal epithelial cells; SNIP1, Smad nuclear interacting protein one; EMT, epithelial-mesenchymal transition; STAT6, signal transducer and activator of transcription six; IFN-γ, interferon gamma; PDLIM2, PDZ and LIM domain protein two; PTEN, phosphatase and tensin homolog; NF-κB, nuclear factor kappa B; A3AR, adenosine A₃ receptor, also known as ADORA3; PDCD4, programmed cell death protein four; STAT3, signal transducer and activator of transcription three; BCL-2, B-cell lymphoma-2; GP130, glycoprotein 130; IKKα, IκB kinase α; IKKβ, IκB kinase β; TNFR2, tumor necrosis factor receptor two; IL1R1, interleukin one receptor type 1; AFTPH, aftiphilin; IL17RD, interleukin 17 receptor D.